ALLIANCES (Details) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) shares	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Alliance Statement [Line Items]
Sales Revenue, Goods, Net	$ 5,461	$ 4,770	$ 10,433	$ 9,350
Alliance revenues	154	237	306	461
Total revenues	5,704	5,144	10,897	10,073
Amortization of deferred income			32	39
Alliance Partners [Member]
Alliance Statement [Line Items]
Sales Revenue, Goods, Net	2,178	1,699	4,098	3,263
Total revenues	2,332	1,936	4,404	3,724
Payments to/(from) alliance partners - Cost of products sold	891	666	1,690	1,287
Payments to/(from) alliance partners - Marketing, selling and administrative	(28)	(14)	(50)	(24)
Payments to/(from) alliance partners - Research and development	1,057	(1)	1,062	(1)
Payments to/(from) alliance partners - Other (income)/expense	(16)	$ (9)	(30)	$ (20)
Receivables - from alliance partners	364		364		$ 322
Accounts payable - to alliance partners	921		921		875
Deferred income from alliances	$ 531		$ 531		$ 467
Nektar Therapeutics [Member]
Alliance Statement [Line Items]
Cost Share, Percentage, Combination Studies	67.50%		67.50%
Percentage of Pretax Profit and Loss Shared with BMS	35.00%		35.00%
License arrangement upfront payment			$ 1,850
Equity Received in Collaborative Partner, Common Stock | shares			8.3
Marketable Securities, Equity Securities	4.80%		4.80%
Common Stock, Voting Rights	5		5
Equity Investment in Collaborative Partner			$ 800
Upfront payment allocated to research and development expenses	$ 1,050		1,050
Consideration for contingent development and regulatory approval			$ 1,800